LOBO EV Technologies partners with Roundtree Lab to manufacture AI-driven medical beds, targeting $11 million in first-year sales.
Quiver AI Summary
LOBO EV Technologies Ltd. has announced a partnership with Roundtree Lab, LLC to manufacture AI-driven medical beds, marking its entry into the healthcare equipment market. This definitive agreement follows a letter of intent from January 2025 and positions LOBO as the exclusive manufacturer of Roundtree’s advanced medical transfer beds, which will integrate AI technology to enhance patient care. The partnership is expected to generate $11 million in sales in the first year, increasing to $88 million by year three, driven by Roundtree's existing relationships with U.S. hospitals. The collaboration aims to leverage LOBO's manufacturing capabilities alongside Roundtree's innovative healthcare solutions to capture a significant portion of the growing U.S. emergency medical equipment market.
Potential Positives
- LOBO's partnership with Roundtree Lab positions the company as the exclusive Original Equipment Manufacturer (OEM) for innovative AI-driven medical beds, enhancing its product portfolio and fostering diversification.
- The agreement is projected to generate significant sales growth, with expected revenues of $11 million in the first year, growing to $88 million by year three, indicating strong financial prospects.
- Entering the expanding U.S. medical device market aligns LOBO with a growing demand for smart medical devices, specifically targeting the need for AI-driven solutions in healthcare, which could enhance its market competitiveness.
- Roundtree's established relationships with U.S. hospitals and healthcare providers are likely to facilitate accelerated adoption of LOBO's medical transfer beds, benefitting from a proven distribution network.
Potential Negatives
- Projected sales figures are contingent on actual orders from Roundtree, which introduces uncertainty and raises concerns about LOBO's ability to achieve these targets.
- The shift from primarily an electric mobility manufacturer to the healthcare equipment sector may divert focus and resources, impacting existing product lines and market positioning.
- The press release relies heavily on forward-looking statements, which may not materialize, indicating potential risk to investor confidence.
FAQ
What is the partnership between LOBO and Roundtree about?
LOBO and Roundtree have formed a partnership for LOBO to manufacture AI-driven medical beds, enhancing healthcare technology.
What are the projected sales figures for LOBO's medical beds?
LOBO anticipates sales of $11 million in the first year, growing to $88 million by year three.
How does this partnership impact the healthcare market?
This partnership enables LOBO to enter the growing U.S. medical device market, targeting smart medical devices and patient transport solutions.
Who will manufacture the medical transfer beds?
LOBO will serve as the exclusive Original Equipment Manufacturer (OEM) for Roundtree's medical transfer beds.
What technology will be integrated into these medical beds?
The medical beds will be equipped with Roundtree's AI system to create advanced AI-driven medical beds for enhanced patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LOBO Hedge Fund Activity
We have seen 2 institutional investors add shares of $LOBO stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 16,384 shares (+inf%) to their portfolio in Q4 2024, for an estimated $29,573
- UBS GROUP AG added 10,495 shares (+85.2%) to their portfolio in Q4 2024, for an estimated $18,943
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Agreement Targets $11 Million in Sales in Year 1,
Growing to $88 Million by Year 3
WUXI, China, March 03, 2025 (GLOBE NEWSWIRE) -- LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative e-bicycle, e-moped, e-tricycle, and electric off-highway four-wheeled shuttle designer, developer, manufacturer and seller, today announced the signing of a definitive agreement with Roundtree Lab, LLC ("Roundtree"), a Wyoming-based leader in AI-driven healthcare solutions. Pursuant to the agreement, LOBO will manufacture medical beds, and Roundtree will continue to upgrade these medical beds by integrating an AI system, turning them into AI-drive medical beds. This partnership signifies LOBO's strategic entry into the burgeoning healthcare equipment market.
Building upon the letter of intent announced on January 22, 2025, this definitive agreement solidifies the collaboration between LOBO and Roundtree. The partnership aims to leverage LOBO’s manufacturing capabilities and expertise in connectivity and multimedia interactive systems to bring Roundtree's patented AI medical bed technology to healthcare facilities across the United States.
Key Highlights of the Agreement:
Exclusive Manufacturing Partnership
LOBO will serve as the exclusive Original Equipment Manufacturer (OEM) for Roundtree's medical transfer beds, utilizing Roundtree's proprietary patents and licenses.
Market Penetration and Expansion
Roundtree's established relationships with U.S. hospitals and healthcare providers will facilitate accelerated market entry and adoption of these advanced medical transfer beds nationwide.
Projected Sales and Growth
LOBO expects that the projected sales arising from the agreement will be $11 million for the first year, $27 million for the second year, and $50 million for the third year. The actual sales revenue depends on the actual orders amount to be placed by Roundtree.
Targeting a Massive and Growing Market
Through this opportunity, LOBO is entering the expanding U.S. medical device market. The demand for smart medical devices, particularly in elderly care and intelligent patient transport, is a key driver of this growth. Within this landscape, AI-driven emergency transfer beds represent a significant opportunity, with Roundtree aiming to capture at least 50% of the U.S. emergency medical equipment market over the next three years. This ambitious target underscores the transformative potential of the technology and the substantial market LOBO is poised to address by combining its manufacturing prowess with Roundtree’s innovative solutions.
Management Commentary
Huajian Xu, CEO of LOBO, stated:
"We are excited to formalize our partnership with Roundtree Lab to deliver medical beds to the U.S. healthcare market. This collaboration aligns with our commitment to innovation and diversification, enabling us to apply our advanced manufacturing expertise to enhance patient care and operational efficiency in medical facilities."
Gordon Franklin, CEO of Roundtree Lab, commented:
"Partnering with LOBO EV Technologies marks a significant milestone in our mission to revolutionize healthcare through AI-driven solutions. LOBO's proven manufacturing excellence and dedication to technological advancement make them the ideal partner to bring our innovative medical transfer beds to market, ultimately improving patient outcomes and healthcare operations."
About LOBO EV Technologies Ltd.
LOBO is an innovative designer, developer, manufacturer and seller of e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons. LOBO also provides automobile information and entertainment software development and design services to customers. Leveraging its cutting-edge technologies in connectivity, multimedia interactive systems and artificial intelligence, LOBO re-defines and develops its products in order to provide users with convenient, affordable and pleasant driving experiences. For more information, visit:
https://www.loboebike.com
and
https://loboev.io
/. Any information displayed on, or that can be accessed through, our website or any other website or any social media is not a part of this press release.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the expected closing date of the public offering and the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements are subject to risk and uncertainties, including, but not limited to, those described in “Risk Factors,” “Operating and Financial Review and Prospects,” “Cautionary Note Regarding Forward-Looking Statements” in the Annual Report on Form 20-F filed with the SEC (File No. 333-270499) on April 30, 2024. LOBO undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
Contact:
For more information, contact:
HORIZON IR
Michael Wei
Hwey@horizonconsultancy.co
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
